Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of DDO-3055 in Healthy Subjects
NCT04775615Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of DDO-3055 in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Hengrui. Primary endpoint: Number of Subjects with Adverse Events up to 14 days. Status: unknown.
02
Drugs
DDO-3055
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04775615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775615.